COMPASS Pathways Triumph In Hard To Treat Depression Ignites Investor Frenzy
COMPASS Pathways (NASDAQ:CMPS) shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in its Phase 3 COMP006 trial for treatment-resistant depression.
Depression Data
The company reported that in the 25 mg arm of its trial, there was a statistically significant reduction in symptom severity for treatment-resistant depression.
In COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001).
Clinically meaningful reduction in MADRS (≥ 25%) observed in a significant number of participants in the 25mg arm of both trials, with 25% in COMP005 and 39% in COMP006, a proprietary formulation of psilocybin.
Additionally, the data suggest that COMP360 is generally well-tolerated, with most treatment-emergent adverse events being mild or moderate. The company is advancing discussions with the FDA to submit a New Drug Application (NDA) in Q4 2026, which could pave the way for new treatment options in a space with limited alternatives.
In June 2025, COMPASS Pathways shared data from the Phase 3 COMP005 trial. A single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity compared to placebo.
Technical Analysis
Currently, the stock is trading 31.15% above its 12-month performance, reflecting strong momentum.
The shares are positioned closer to their 52-week highs than lows, indicating bullish sentiment among investors.
The RSI is at a neutral level, while the MACD is below its signal line, suggesting bearish pressure on the stock. This combination indicates mixed momentum, as the stock has not yet established a clear trend direction.
- Key Resistance: $8.00
- Key Support: $6.00
Analyst Consensus & Recent Actions
The stock carries a Buy rating with an average price target of $18.15. Recent analyst moves include:
- RBC Capital: Outperform (Raises Target to $21)
- Morgan Stanley: Overweight (Raises Target to $11)
- BTIG: Buy (Raises Target to $14)
Top ETF Exposure
- ADVISORSHARES PSYCHEDELICS ETF (NYSE:PSIL): 8.62% Weight
CMPS Price Action: Compass Pathways shares were up 23.06% at $7.15 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Crypto prices
More
